KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.
List of Patents:
- Chimeric Animal Model Susceptible to Human Hepatitis C Virus Infection
- Animal Model Having a Chimeric Human Liver
- Animal Model Having a Chimeric Human Liver - Toxicity
- Malarial Animal Model Having a Chimeric Human Liver